Build Confidence in Your Radiopharmaceutical Program
From radio labeling to PDX efficacy and PET/CT imaging*, Champions Oncology delivers translational data that accelerates your path to clinic.
- Preclinical Oncology CRO Services | Clinical Trial Specialty Testing
- Radiopharmaceutical Development
A Trusted Partner in Radiopharmaceutical Development
Radiopharmaceuticals are transforming oncology research, offering highly targeted delivery of radiation to tumors with reduced off-target effects. At Champions Oncology, we provide end-to-end support for biopharma companies advancing radiopharmaceutical therapies. Our programs combine deep oncology expertise, clinically relevant PDX models, and advanced translational imaging* to generate decision-driving data at every stage.
Whether you’re evaluating a novel payload, refining your targeting strategy, or preparing for IND-enabling studies, Champions offers the infrastructure, expertise, and models to move forward with confidence.
Why Radiopharmaceuticals Matter
Radiopharmaceuticals use radioactive isotopes linked to peptides, antibodies, or other targeting agents to diagnose or treat cancer. These therapies allow for:
- Precise tumor targeting
- Minimized systemic toxicity
- Integrated diagnostic and therapeutic strategies (theranostics)
- Promising applications in solid tumors and resistant cancers
Champions supports radiopharmaceutical developers with tools that reflect how these therapies behave in real patients—bridging the gap between discovery and clinic.
What Sets Champions Apart
PDX + Radiopharma
We are the only preclinical CRO to pair radiopharmaceutical testing with clinically annotated patient-derived xenograft (PDX) models, representative of today’s clinical trial population, delivering unmatched translational relevance.
Our PDX platform captures both intra- and inter-tumor heterogeneity, mirroring the diversity of the real-world patient population. This allows for a more nuanced understanding of targeting performance, efficacy, and variability. We also offer tissue microarrays (TMAs) from our model library to assess target expression across a broad range of tumor types prior to proceeding in vivo.
Access to Scarce Isotopes
Our licensed facility enables radiolabeling with key isotopes like Actinium-225, Astatine-211, Copper-64, Copper-67, Indium-111, Lead-212, Lutetium-177, Terbium-161, Yttrium-90, and Zirconium-89 to support a wide range of targeted therapies.
Integrated Clinical Database
Our proprietary PDX database connects molecular data, treatment outcomes, and pharmacology insights across hundreds of patient tumors—helping you select the right models and interpret results in a clinical context.
Full Lifecycle Support
From conjugation to efficacy, Champions is equipped to run complex studies with a seamless handoff from radiochemistry to in vivo.
Our Radiopharmaceutical Services
We provide a comprehensive suite of RPT services designed to support early discovery through late-stage validation.
We provide small-scale conjugation and radiolabeling services to support early-stage development and screening. Our team ensures reproducibility and quality across a wide range of isotopes and molecular formats.
- Conjugation of bifunctional chelators to antibodies, peptides, or fragments
- Radiolabeling with Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211, Tb-161, Cu-64, Zr-89
Before moving in vivo, we help you understand targeting efficiency, biological activity, and compound behavior at the cellular level. Our in vitro assays are designed to inform go/no-go decisions and de-risk study design.
- Stability studies in formulation, serum, and plasma (mouse, human, etc.)
- Cell binding, uptake, and internalization assays
- Immunoreactivity (saturation, dissociation, blocking assays)
- Cytotoxicity and functional assays using relevant models (e.g., PDX cell lines)
Champions’ in vivo radiopharmaceutical studies leverage our expansive PDX library, offering clinically relevant models that capture the complexity of human tumors. This includes intra- and inter-tumor heterogeneity, varied treatment responses, and the ability to pre-screen target expression via TMAs.
- Biodistribution and dosimetry (with select partners)
- Pharmacokinetic profiling
- Efficacy testing using PDX and CDX models
- *Advanced imaging with PET/CT and IVIS (luciferase-tagged models)
*in partnership with Medicines Discovery Catapult
Post-study, we offer a range of ex vivo analyses to extend the value of your data. From histology to molecular imaging and stability assessments, our analytical tools help you interrogate response and mechanism with precision.
- Histology, IHCFFPE tissue processing
- Mass spectrometry (non-radiolabeled)
- Stability by radio-TLC,
PET/CT Imaging
In Partnership with Medicines Discovery Catapult. Champions offers high-resolution, non-invasive PET/CT imaging for biodistribution, receptor occupancy, and tumor targeting studies. This includes:
- Dynamic and static imaging with quantitative readouts
- Longitudinal tracking of tracer uptake
- 3D volumetric outputs analyzed using PMOD software
- Integrated anatomical and functional data for full spatial context
Final reports include annotated images, quantitative graphs, and summary videos where applicable.
Flexible Study Design & Realistic Timelines
We understand that every program is unique. Champions offers flexible study designs based on your molecule, goals, and model availability. Our team works with you to:
- Define the most appropriate study format
- Align timelines with regulatory milestones
- Leverage co-treatments or multi-arm designs where appropriate
We prioritize speed, transparency, and collaboration—so you get the data you need, when you need it.
Let’s Build the Right Study Together
Champions Oncology is your partner in developing smarter, safer radiopharmaceuticals. Our team brings together the right models, the right isotopes, and the right tools to help you advance from early feasibility to confident IND submission, —with data that stands up to scrutiny.
What isotopes can you work with, and do you supply them in-house?
We currently support radiolabeling with Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211, Tb-161, Cu-64, and Zr-89. These are sourced through our licensed facility, enabling dependable access to isotopes that are often difficult to obtain.
Can you help us evaluate targeting strategies before we commit to efficacy studies?
Yes. PET imaging and biodistribution studies are available through our partnership with Medicines Discovery Catapult to assess tracer localization and kinetics prior to efficacy testing.
What types of models are available for efficacy studies?
We offer both CDX and PDX models. Models are selected from our proprietary Lumin database, which links multi-omics molecular profiles and treatment responses to improve clinical relevance.